Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Nov;26(5):535–545. doi: 10.1111/j.1365-2125.1988.tb05293.x

Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

PMCID: PMC1386630  PMID: 2905154

Abstract

1. The antihypertensive efficacy of two different doses of the calcium antagonist felodipine was evaluated in patients with hypertension persisting despite beta-adrenoceptor blocker therapy. Following a single-blind placebo period of 4 weeks, patients were randomized to placebo (n = 36), felodipine 5 mg twice daily (n = 39) and felodipine 10 mg twice daily (n = 35) for another 4 weeks. beta-adrenoceptor blocker therapy remained unchanged throughout the study. 2. Effects on blood pressure (BP) were evaluated after the first dose and after chronic dosing at 2 h after dosing and the end of the dosing interval (12 h). 3. Felodipine decreased systolic and diastolic BP by 30-35/20-25 mm Hg at 2 h. These decreases were similar after acute and chronic treatment. Twelve hours after dosing, decreases of 15-20/10-15 mm Hg were observed compared to 10/5 mm Hg on placebo, and half of the patients still had a controlled BP (supine diastolic BP less than 90 mm Hg). BP responses were rather similar for both doses of felodipine at 2 and 12 h. 4. Multiple regression analysis showed that both initial BP level and plasma felodipine concentrations were significant predictors of the BP response to felodipine, but age was not. 5. Adverse effects attributed to felodipine were mainly related to vascular symptoms (primarily flushing and ankle swelling); these occurred in about 30% of patients, and were pronounced in three patients (4%). 6. Felodipine is therefore highly effective in lowering BP of hypertensive patients on chronic beta-adrenoceptor blocker therapy, with no evidence for a gradual lowering of the BP or for development of tolerance. Both initial BP level and plasma concentrations are better indicators of antihypertensive efficacy of this calcium antagonist than age.

Full text

PDF
535

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson O., Bengtsson C., Elmfeldt D., Haglund K., Hedner T., Seideman P., Sjöberg K. H., Strömgren E., Aberg H., Ostman J. Short-term effects of felodipine, a new dihydropyridine, in hypertension. Br J Clin Pharmacol. 1984 Mar;17(3):257–263. doi: 10.1111/j.1365-2125.1984.tb02340.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruun N. E., Ibsen H., Nielsen F., Nielsen M. D., Moelbak A. G., Hartling O. J. Lack of effect of nifedipine on counterregulatory mechanisms in essential hypertension. Hypertension. 1986 Aug;8(8):655–661. doi: 10.1161/01.hyp.8.8.655. [DOI] [PubMed] [Google Scholar]
  3. DiBona G. F. Effects of vasodilator antihypertensive agents on renal function. J Cardiovasc Pharmacol. 1987;9 (Suppl 1):S14–S16. [PubMed] [Google Scholar]
  4. Edgar B., Collste P., Haglund K., Regårdh C. G. Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. Clin Invest Med. 1987 Sep;10(5):388–394. [PubMed] [Google Scholar]
  5. Edgar B., Regårdh C. G., Johnsson G., Johansson L., Lundborg P., Löfberg I., Rönn O. Felodipine kinetics in healthy men. Clin Pharmacol Ther. 1985 Aug;38(2):205–211. doi: 10.1038/clpt.1985.160. [DOI] [PubMed] [Google Scholar]
  6. Ibsen H., Rasmussen K., Jensen H. A., Leth A. Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension. Acta Med Scand. 1978;203(5):419–423. doi: 10.1111/j.0954-6820.1978.tb14899.x. [DOI] [PubMed] [Google Scholar]
  7. Kiowski W., Bühler F. R., Fadayomi M. O., Erne P., Müller F. B., Hulthén U. L., Bolli P. Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol. 1985 Dec 6;56(16):81H–85H. doi: 10.1016/0002-9149(85)90549-1. [DOI] [PubMed] [Google Scholar]
  8. Leenen F. H., Prowse S. Time-course of changes in cardiac hypertrophy and pressor mechanisms in two-kidney, one clip hypertensive rats during treatment with minoxidil, enalapril or after uninephrectomy. J Hypertens. 1987 Feb;5(1):73–83. doi: 10.1097/00004872-198702000-00011. [DOI] [PubMed] [Google Scholar]
  9. Leonetti G., Gradnik R., Terzoli L., Fruscio M., Rupoli L., Zanchetti A. Felodipine, a new vasodilating drug: blood pressure, cardiac, renal, and humoral effects in hypertensive patients. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):392–398. [PubMed] [Google Scholar]
  10. Levine M. A., Ogilvie R. I., Leenen F. H. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin Pharmacol Ther. 1988 Jan;43(1):39–48. doi: 10.1038/clpt.1988.9. [DOI] [PubMed] [Google Scholar]
  11. Littler W. A., Young M. A. The effect of nicardipine on blood pressure, its variability and reflex cardiac control. Br J Clin Pharmacol. 1985;20 (Suppl 1):115S–119S. doi: 10.1111/j.1365-2125.1985.tb05152.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ljung B. Vascular selectivity of felodipine. Drugs. 1985;29 (Suppl 2):46–58. doi: 10.2165/00003495-198500292-00011. [DOI] [PubMed] [Google Scholar]
  13. Man in 't Veld A. J., Wenting G. J., Boomsma F., Verhoeven R. P., Schalekamp M. A. Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. Br J Clin Pharmacol. 1980 Jun;9(6):547–551. doi: 10.1111/j.1365-2125.1980.tb01079.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Müller F. B., Ha H. R., Hotz H., Schmidlin O., Follath F., Bühler F. R. Once a day verapamil in essential hypertension. Br J Clin Pharmacol. 1986;21 (Suppl 2):143S–147S. doi: 10.1111/j.1365-2125.1986.tb02863.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reeves R. A., Smith D. L., Leenen F. H. Hemodynamic interaction of nonselective vs. beta-1-selective beta-blockade with hydralazine in normal humans. Clin Pharmacol Ther. 1987 Mar;41(3):326–335. doi: 10.1038/clpt.1987.35. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES